Aerie Pharmaceuticals Inc.

05/24/2022 | Press release | Distributed by Public on 05/24/2022 05:33

Aerie Pharmaceuticals Announces First Participant Dosed in the Phase 3 Registrational COMET-2 Study of AR-15512 for the Treatment of Dry Eye Disease